US-based gene therapy developer Lexeo Therapeutics has raised $100m in a series B round featuring pharmaceutical company Lundbeck and life sciences real estate investment trust Alexandria Real Estate Equities
Asset managers D1 Capital Partners and Eventide Asset management co-led the round and were joined by Verition Fund Management, Laurion Capital Management, Longitude Capital, Gray’s Creek Capital, Omega Funds, Janus Henderson Investors, PBM Capital, Woodline Partners and Invus Capital.
Lundbeck made its commitment through its corporate venturing unit Lundbeckfonden Ventures while Alexandria Real Estate Equities invested through its strategic investment arm, Alexandria Venture Investments.
Since its founding in 2018, Lexeo has worked to develop gene therapies to treat certain genetically-derived diseases like Alzheimer’s, Batten Disease and certain cardiovascular conditions. It will use the funding to advance its clinical stage drug candidates.
Lexeo’s $85m series A round was co-led by Longitude Capital and Omega Funds in January 2021 and included Lundbeckfonden, Alexandria Venture Investments, Alzheimer’s Drug Discovery Foundation, PBM Capital, Janus Henderson Investors, Woodline Partners and Invus Capital.
R Nolan Townsend, chief executive of Lexeo, said: “As we embark on our next phase of growth, we are highly encouraged by the support of this diverse range of long-term focused investors participating in our series B financing.
“With this capital infusion, we plan to advance our clinical stage pipeline to meaningful near-term data catalysts while establishing portfolio leadership positions in cardiac gene therapy and the genetics of Alzheimer’s disease.”
